Clinical Trial Update: Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. [Phase 2]

View source ↗

Summary

Phase 2 randomized, observer-blind study evaluating immunogenicity and safety of a Lyme borreliosis vaccine in healthy adults (18-65). Results posted after comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lyme Disease

Snippet

Sponsor: Pfizer | Conditions: Lyme Borreliosis | Phase 2 | Status: COMPLETED | Results posted: 2021-06-30